1. Targeting FLT3 Mutations in Acute Myeloid Leukemia

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. AML Basic Facts

4. FLT3 Mutations in AML

5. Mutational Complexity of AML

6. PCR Assay for FLT3-ITD Mutation

7. Practical Issues in FLT3 Testing PCR vs NGS

8. FLT3 Inhibitors in Clinical Development

9. 7+3/Midostaurin vs 7+3/Placebo CALGB 10603 (RATIFY), Phase 3

10. Overall Survival CALGB 10603 (RATIFY), Phase 3

11. Overall Survival After AlloHSCT in CR1 CALGB 10603 (RATIFY), Phase 3

12. Analysis of Maintenance Therapy CALGB 10603 (RATIFY), Phase 3

13. DFS During Maintenance CALGB 10603 (RATIFY), Phase 3

14. DFS After Maintenance CALGB 10603 (RATIFY), Phase 3

15. NPM1/FLT3-ITD Genotype Analysis CALGB 10603 (RATIFY), Phase 3

16. Midostaurin Drug Interactions Use With Strong CYP3A4 Inhibitors

17. Midostaurin Induction and Maintenance AMLSG 16-10, Phase 2

18. RFS for Midostaurin vs Historical Control AMLSG 16-10, Phase 2

19. Sorafenib in Newly Diagnosed AML < 60 Years SORAML, Phase 2 RCT*

20. SORAML Survival Endpoints

21. Sorafenib Plus Azacytidine FLT3-ITD+ R/R AML, Phase 2 Study

22. Sorafenib Plus Azacytidine Newly Diagnosed FLT3-ITD+ AML

23. Quizartinib FLT3-ITD+ R/R AML

24. Quizartinib in FLT3-ITD+ R/R AML Randomized Phase 2 Study

25. Quizartinib as a Bridge to Transplant FLT3-ITD+ AML After Salvage Chemotherapy Failure

26. Quizartinib Plus Azacytidine or LDAC Phase 1/2 Trial

27. Gilteritinib in FLT3-Mutated R/R AML CHRYSALIS, Phase 1/2

28. Gilteritinib in FLT3-Mutated R/R AML CHRYSALIS Subset Analysis

29. Gilteritinib in Newly Diagnosed AML Preliminary Phase 1 Results

30. Crenolanib in FLT3-Mutated R/R AML Phase 2 Results

31. Crenolanib With Standard AML Therapy Phase Ib Study

32. Future Directions

33. Key Takeaways

34. Abbreviations

35. Abbreviation Cont

36. Abbreviation Cont

37. Abbreviations Cont